The FDA has accepted for review the New Drug Application for Trevyent, a drug-device combination product for the treatment of pulmonary arterial hypertension.
The FDA has granted Orphan Drug designation to sotatercept for the treatment of patients with pulmonary arterial hypertension.
The new definition of pulmonary hypertension has demonstrated validity in a study recently published in CHEST, which showed an association between elevated pulmonary vascular resistance (PVR) and increased risk for mortality within 30 days of heart transplant. This risk can be sustained even with lower pulmonary arterial pressures. This retrospective study included 32,465 adult participants…
Treatment with the next-generation potent prostacyclin receptor agonist ralinepag reduced pulmonary vascular resistance compared with placebo in patients with symptomatic pulmonary arterial hypertension.
Researchers gauged the effect of concomitant pulmonary hypertension on clinical outcomes and late-onset progression of tricuspid regurgitation after mitral valve relapse for rheumatic mitral stenosis.
Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women.
An implantable hemodynamic monitor safely monitored hemodynamic changes in patients with severe pulmonary arterial hypertension.
Inhaled epoprostenol delivered via high-flow nasal cannula increased oxygenation among patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction.